TCGA-E2-A1IN-01A-11R-A13Q-07
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
- overall_survival_months
- 22
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- TGF_BETA_SIGNALING+0.370
- ANGIOGENESIS+0.330
- UV_RESPONSE_DN+0.330
- PANCREAS_BETA_CELLS+0.280
- MYC_TARGETS_V1+0.230
- NOTCH_SIGNALING+0.220
- PROTEIN_SECRETION+0.210
- APICAL_SURFACE+0.180
- COAGULATION+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.570
- INTERFERON_GAMMA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.360
- IL6_JAK_STAT3_SIGNALING-0.360
- E2F_TARGETS-0.330
- G2M_CHECKPOINT-0.320
- UV_RESPONSE_UP-0.270
- MITOTIC_SPINDLE-0.250
- PI3K_AKT_MTOR_SIGNALING-0.250
- TNFA_SIGNALING_VIA_NFKB-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AO-A12C-01A-11R-A10J-07 | — | A | 0.776 |
| 2 | TCGA-XF-A9SV-01A-21R-A42T-07 | — | — | 0.766 |
| 3 | TCGA-B6-A0RN-01A-12R-A084-07 | — | B | 0.765 |
| 4 | SRR8518264 | — | D | 0.742 |
| 5 | BSR_08_0188_C3_S52 | — | A | 0.740 |
| 6 | SRR8518172 | — | E | 0.735 |
| 7 | SNU182_LIVER | HCC | — | 0.731 |
| 8 | bf33f73b-a3b5-4585-a759-7bea4384e703 | — | — | 0.729 |
| 9 | SRR10900592 | — | — | 0.724 |
| 10 | SRR8518416 | — | E | 0.717 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.330 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.120 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.050 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.030 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |